The Age Related Eye Disease Study (AREDS) represents a pivotal moment in ophthalmic research, significantly enhancing our knowledge of how specific nutrients can influence the progression of common age-related eye conditions. This groundbreaking research, conducted by the National Eye Institute, focused primarily on Age-related Macular Degeneration (AMD) and cataracts, two leading causes of vision loss among older adults. Understanding the Age Related Eye Disease Study is crucial for anyone concerned about their long-term eye health, especially those with a family history of AMD or early signs of the condition.
What is the Age Related Eye Disease Study (AREDS)?
The original Age Related Eye Disease Study was a major clinical trial initiated in 1996, involving thousands of participants across the United States. Its primary objective was to investigate the effects of high-dose vitamin and mineral supplements on the progression of AMD and cataract development. Researchers aimed to determine if specific antioxidant vitamins and minerals could protect the eyes from the damage associated with aging.
Participants in the Age Related Eye Disease Study were divided into several groups, receiving either a placebo or different combinations of supplements. The study meticulously tracked changes in their vision and the severity of their AMD over many years. This careful monitoring allowed scientists to draw robust conclusions about the efficacy of the tested formulations.
Key Findings of the Original AREDS Study
The results of the initial Age Related Eye Disease Study, published in 2001, were highly significant. The study found that a specific high-dose combination of antioxidants and zinc could reduce the risk of advanced AMD progression by about 25% over a five-year period. This was a substantial breakthrough for millions at risk.
The specific formulation identified by the Age Related Eye Disease Study included:
- Vitamin C: 500 mg
- Vitamin E: 400 IU
- Beta-carotene: 15 mg (equivalent to 25,000 IU of Vitamin A)
- Zinc: 80 mg (as zinc oxide)
- Copper: 2 mg (as cupric oxide, added to prevent copper deficiency associated with high zinc intake)
It is important to note that the original Age Related Eye Disease Study formula was found to be beneficial only for individuals with intermediate AMD or advanced AMD in one eye, not for those with minimal AMD or no AMD. Furthermore, the study found no significant benefit of these supplements in preventing or slowing the progression of cataracts.
Introducing AREDS2: An Evolution in Eye Health Research
Following the success of the original Age Related Eye Disease Study, researchers recognized the need for further investigation to refine the supplement formulation. The Age Related Eye Disease Study 2 (AREDS2) was launched to address several key questions and potential concerns arising from the initial study. One primary concern was the inclusion of beta-carotene, which had been linked to an increased risk of lung cancer in smokers and former smokers.
AREDS2 also explored the potential benefits of adding other nutrients, such as omega-3 fatty acids (DHA and EPA) and two additional antioxidants, lutein and zeaxanthin, which are naturally found in the macula. The goal was to create an even safer and potentially more effective supplement formula for slowing AMD progression.
AREDS2: The Updated Formula and Its Benefits
The Age Related Eye Disease Study 2, published in 2013, confirmed many of the original findings and introduced important modifications to the supplement composition. The most significant change was the removal of beta-carotene and its replacement with lutein and zeaxanthin.
The updated AREDS2 formulation includes:
- Vitamin C: 500 mg
- Vitamin E: 400 IU
- Lutein: 10 mg
- Zeaxanthin: 2 mg
- Zinc: 25-80 mg (as zinc oxide)
- Copper: 2 mg (as cupric oxide)
The Age Related Eye Disease Study 2 found that the new formulation, particularly with lutein and zeaxanthin replacing beta-carotene, was equally effective in reducing the risk of advanced AMD progression. For those who consumed low levels of lutein and zeaxanthin in their diet, adding these nutrients to the supplement provided an additional benefit. Importantly, the AREDS2 formula eliminated the lung cancer risk associated with beta-carotene for smokers.
The study also investigated omega-3 fatty acids but found no additional benefit in slowing AMD progression when added to the AREDS formula. Therefore, they are not typically included in the recommended AREDS2 supplement formulations.
Who Should Consider AREDS/AREDS2 Supplements?
Understanding the Age Related Eye Disease Study’s findings is crucial for determining who might benefit from these supplements. The AREDS and AREDS2 formulations are specifically recommended for individuals who have been diagnosed with:
- Intermediate Age-related Macular Degeneration (AMD): Characterized by extensive medium-sized drusen or at least one large drusen in one or both eyes.
- Advanced AMD in one eye: Even if the other eye has less severe AMD.
It is critical to emphasize that these supplements are not a cure for AMD, nor are they effective in preventing AMD in healthy individuals or those with early AMD. They are designed to slow the progression of the disease in specific stages. Always consult with your eye care professional to determine if AREDS or AREDS2 supplements are appropriate for your individual condition.
Beyond Supplements: Lifestyle and Eye Health
While the Age Related Eye Disease Study highlights the role of specific nutrients, maintaining overall eye health involves more than just supplements. A holistic approach includes several lifestyle factors:
- Healthy Diet: Consuming a diet rich in fruits, vegetables, and leafy greens provides a wide array of antioxidants beneficial for eye health.
- Regular Exercise: Physical activity helps maintain overall cardiovascular health, which is linked to ocular health.
- Smoking Cessation: Smoking is a major risk factor for AMD and many other eye diseases.
- UV Protection: Wearing sunglasses that block 100% of UVA and UVB rays can protect your eyes from harmful sun exposure.
- Regular Eye Exams: Comprehensive dilated eye exams are essential for early detection and management of eye conditions.
These lifestyle choices, combined with appropriate supplementation based on the Age Related Eye Disease Study findings, offer the best strategy for preserving vision as you age.
Conclusion
The Age Related Eye Disease Study and its successor, AREDS2, have profoundly impacted our approach to managing age-related macular degeneration. By identifying specific nutrient combinations that can slow disease progression, these studies offer hope and a tangible strategy for millions. If you have intermediate AMD or advanced AMD in one eye, discussing the AREDS2 formulation with your eye care professional is a vital step. Remember, personalized medical advice is always necessary to ensure the best outcomes for your unique eye health needs.